Annual tuberculosis screening in patients on biologics has questionable value - 05/04/24
Doi : 10.1016/j.jaad.2024.02.051
Madison N. Kist, BS a, Ryan Svoboda, MD, MS b, Steven Maczuga, MS c, Li Wang, PhD d, Galen T. Foulke, MD c, d, Matthew F. Helm, MD c, ⁎ 
a The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
b Department of Dermatology, UMass Medical Center, Worcester, Massachusetts
c Department of Dermatology, Milton S. Hershey Penn State Medical Center, Hershey, Pennsylvania
d Department of Public Health Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
∗Correspondence to: Matthew F. Helm, MD, Department of Public Health Sciences, The Pennsylvania State University College of Medicine, 500 University Drive, Suite 100, Hershey, PA 17033-0850Department of Public Health SciencesThe Pennsylvania State University College of Medicine500 University DriveSuite 100, HersheyPA17033-0850
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 05 April 2024
Keywords : biologic agent, interferon-gamma release assays, latent tuberculosis infection, purified protein derivative skin test
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by the Penn State IRB (STUDY0006364). |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?